CoChat
Sign Up
Cited by 984Coenzyme Q10 studies and effectsParkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline

Shults, Clifford W.·2002·Archives of Neurology
DOI 10.1001/archneur.59.10.1541
Open this paper in CoChat — free account

Abstract

BACKGROUND: Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. OBJECTIVE: To determine whether a range of dosages of coenzyme Q10 is safe and well tolerated and could slow the functional decline in PD. DESIGN: Multicenter, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging trial. SETTING: Academic movement disorders clinics. PATIENTS: Eighty subjects with early PD who did not require treatment for their disability. INTERVENTIONS: Random assignment to placebo or coenzyme Q10 at dosages of 300, 600, or 1200 mg/d. MAIN OUTCOME MEASURE: The subjects underwent evaluation with the Unified Parkinson Disease Rating Scale (UPDRS) at the screening, baseline, and 1-, 4-, 8-, 12-, and 16-month visits. They were followed up for 16 months or until disability requiring treatment with levodopa had developed. The primary response variable was the change in the total score on the UPDRS from baseline to the last visit. RESULTS: The adjusted mean total UPDRS changes were +11.99 for the placebo group, +8.81 for the 300-mg/d group, +10.82 for the 600-mg/d group, and +6.69 for the 1200-mg/d group. The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was.09, which met our prespecified criteria for a positive trend for the trial. A prespecified, secondary analysis was the comparison of each treatment group with the placebo group, and the difference between the 1200-mg/d and placebo groups was significant (P =.04). CONCLUSIONS: Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.

Integrity signals

Registry

Crossref · 10.1001/archneur.59.10.1541

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Parkinson's patients in early stages supplemented with 1200 mg per day delayed progression of deterioration of disease.

    “In the next trial, Parkinson’s patients in the early stages of the development of the disease, supplemented with 1200 mg per day (a safe and well-tolerated dose) delayed the progression of deterioration of the disease (Shults et al. 2002).”

    From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Shults et al. 2002

  • In a phase II clinical trial of CoQ10 in early PD, there was a statistically significant dose-dependent reduction in UPDRS score in subjects assigned to CoQ10 compared to placebo.

    “CoQ10 was safe and well tolerated at dosages of up to 1200 mg/day and a statistically significant dose-dependent reduction in UPDRS score was evident in subjects assigned to CoQ10 compared to those assigned to placebo.”

    From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [160]

  • In a phase II clinical trial of CoQ10 in early PD, CoQ10 was safe and well tolerated at dosages up to 1200 mg/day.

    “CoQ10 was safe and well tolerated at dosages of up to 1200 mg/day and a statistically significant dose-dependent reduction in UPDRS score was evident in subjects assigned to CoQ10 compared to those assigned to placebo.”

    From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [160]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Shults, C. W.
Affiliations
University of California San Diego (US)
Corresponding author
Shults, Clifford W.
Venue
Archives of Neurology
Publisher
American Medical Association (AMA)
Published
2002-10-01
Volume
59
Issue
10
Pages
1541
ISSN
0003-9942 (ISSN-L)
DOI
10.1001/archneur.59.10.1541
OpenAlex
W2171471740
Cited by
984
References
51
Citations by year
2026: 21 · 2025: 23 · 2024: 18 · 2023: 24 · 2022: 29 · 2021: 28 · 2020: 28 · 2019: 21 · 2018: 18 · 2017: 20 · 2016: 24 · 2015: 22 · 2014: 36 · 2013: 42 · 2012: 52
FWCI
20.80
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
coenzyme Q10, Parkinson's disease, early-stage Parkinson's disease, functional decline, Unified Parkinson's Disease Rating Scale, safety and tolerability, disease progression, neuroprotection
MeSH terms
Administration, Oral, Aged, Antioxidants, Coenzymes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Persons with Disabilities, Disabled Persons, Humans, Male, Middle Aged, Parkinson Disease, Ubiquinone, Treatment Outcome, Disease Progression, Cytoprotection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review